SCCS Final Opinion on Methyl Salicylate
Methyl Salicylate is used in several fragrance formulation and as a flavouring and soothing agent in oral hygiene products. A classification as “Toxic for Reproduction Category 2” and “Skin sensitizer Category 1B” was recommended in a RAC opinion (2019) and the European Commission asked the SCCS to carry out a safety assessment on Methyl Salicylate. The SCCS' final opinion on the ingredient was recently released.
Picture of Marta Pinto

Marta Pinto

Regulatory Affairs Associate


Methyl Salicylate (INCI name: methyl 2-hydroxybenzoate) is the ester of methyl alcohol and salicylic acid. According to different studies, Salicylic acid is the main metabolic product of Methyl Salicylate by hydrolysis.

In cosmetics and personal care products, Methyl Salicylate is used as a denaturant, flavouring, oral care, perfuming and soothing agent. It is used as an ingredient in several fragrance mixture and as a flavouring and soothing agent in oral hygiene products. Methyl Salicylate is not currently included in the annexes of the European Cosmetics Regulation (No. 1223/2009), which means its use is not restricted in cosmetic products.

In 2019, the European Risk Assessment Committee (RAC) of the European Chemicals Agency (ECHA) issued an opinion on Methyl Salicylate, recommending a classification as “Toxic for Reproduction Category 2” and “Skin sensitizer Category 1B” for this ingredient, based on a read across with data available on Salicylic Acid. Following the RAC opinion, an amendment to Annex VI of the CLP Regulation (Regulation (EC) 1272/2008 on classification labelling and packaging of chemical substances and mixtures) is expected.

According to the EU Cosmetics Regulation, the use of substances classified as CMR (carcinogenic, mutagenic or toxic for reproduction) shall be prohibited in cosmetic products, unless, by way of exception, specific conditions are fulfilled. A CMR classified in category 2 may be used in cosmetic products where the substance has been evaluated by the European Commission’s Scientific Committee on Consumer Safety (SCCS) and found safe for use in cosmetic products.

Considering the RAC opinion and the expected classification of Methyl Salicylate as a “Toxic for Reproduction Category 2”, a dossier was submitted by Cosmetics Europe to support the safety of Methyl Salicylate. The Commission asked the SCCS to carry out a safety assessment on Methyl Salicylate, taking into account the dossier submitted and also the maximum concentration of this ingredient used in the different categories of cosmetic products.


Last month, the SCCS has issued its final opinion on Methyl Salicylate. This ingredient should be regarded as a weak skin sensitizer (in humans) and eye irritant. The Committee concluded that Methyl Salicylate is considered safe when used in cosmetics up to the maximum concentration provided in the dossier submitted (presented in the table below).

The SCCS also expressed some concerns regarding the use of this ingredient in cosmetics and personal care products. As Methyl Salicylate can be used in consumer products other than cosmetics (e.g., household cleaning products, air care products, biocides, polishes, waxes, etc.), it can increase the systemic exposure dose with a possibility to exceed the safe level. Additionally, Methyl Salicylate is metabolized in the body to Salicylic Acid (also classified as a reprotoxicant, used in cosmetics, found safe under the conditions stated in the Opinion SCCS/1601/18), and therefore, the combined exposure to cosmetic products containing various salicylates may increase the systemic exposure dose with a possibility to exceed the safe level.

As wintergreen oil may contain up to 99% Methyl Salicylate, the calculation of Methyl Salicylate content in a cosmetic must consider any fraction coming from wintergreen oil.

If you wish to get more information on the safety of cosmetic ingredients, feel free to contact us at


  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.
  2. Scientific Committee on Consumer Safety (SCCS). Opinion on Methyl salicylate (methyl 2-hydroxybenzoate). SCCS/1633/21. 2021
  3. Scientific Committee on Consumer Safety (SCCS). Opinion on Salicylic acid (CAS 69-72-7). Submission I. SCCS/1601/18. 2019


medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »